Symposia: Lymphomas: Translational – Molecular and Genetic
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Clinical trials, Adult, Combination therapy, Apoptosis, Translational Research, Lymphomas, Non-Hodgkin lymphoma, CHIP, Clinical Research, Genomics, B Cell lymphoma, Immune mechanism, Diseases, Indolent lymphoma, Real-world evidence, Immunology, Aggressive lymphoma, Treatment Considerations, Biological therapies, Immunotherapy, Registries, Lymphoid Malignancies, Computational biology, Biological Processes, Monoclonal Antibody Therapy, Molecular biology, Technology and Procedures, Study Population, Human, Pathogenesis, Measurable Residual Disease , Machine learning, Omics technologies
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Clinical trials, Adult, Combination therapy, Apoptosis, Translational Research, Lymphomas, Non-Hodgkin lymphoma, CHIP, Clinical Research, Genomics, B Cell lymphoma, Immune mechanism, Diseases, Indolent lymphoma, Real-world evidence, Immunology, Aggressive lymphoma, Treatment Considerations, Biological therapies, Immunotherapy, Registries, Lymphoid Malignancies, Computational biology, Biological Processes, Monoclonal Antibody Therapy, Molecular biology, Technology and Procedures, Study Population, Human, Pathogenesis, Measurable Residual Disease , Machine learning, Omics technologies
Saturday, December 7, 2024: 2:00 PM-3:30 PM
Pacific Ballroom Salons 15-17
(Marriott Marquis San Diego Marina)
Moderators:
Bertrand Nadel, PhD, Centre D'Immunologie De Marseille-Luminy
and
Jessica Okosun, MB BChir PhD, Barts Cancer Institute, Queen Mary University of London
Disclosures:
Okosun: Incyte: Consultancy; Genmab: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Research Funding.
This session will present novel data pertaining to mechanisms of lymphoma genesis in aggressive B- and T-cell lymphomas and associated vulnerabilities
2:30 PM
2:45 PM
3:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH